Letrozole

Letrozole is chosen when another AI has failed and a more aggressive intervention is needed, or when gynecomastia is actively developing and stopping it quickly is the priority. The power that makes it dangerous in routine use makes it effective in this specific scenario.

Use case: High-potency emergency estrogen control, not routine first-line use.

Administration: Very small changes in dose can create very large changes in estrogen status.

Decision rule: Keep this for cases where milder tools are not enough or where gynecomastia is actively progressing.

Stop or reduce if: the user shows classic low-estrogen symptoms.

Letrozole is a third-generation non-steroidal aromatase inhibitor, the same class as anastrozole, but substantially more potent. It is capable of reducing estradiol levels by 95–98% at full doses, compared to 70–80% with anastrozole. This is why its primary medical use is breast cancer treatment in postmenopausal women, where near-complete estrogen suppression is the goal.

In the performance context, this potency means letrozole has a very narrow therapeutic window. The doses that provide meaningful estrogen control in a supraphysiological androgen environment are close to the doses that crash estrogen entirely. For most users running testosterone at typical cycle doses, anastrozole or exemestane offer sufficient potency with much more controllable titration.

When letrozole makes sense: Acute gynecomastia intervention. If a user develops progressing gynecomastia lumps (not just sensitivity, actual glandular tissue growth), a short, aggressive letrozole protocol can be an effective emergency intervention. Starting at 1–2.5mg daily for a brief window while gynecomastia is actively growing is one of the only situations where letrozole’s power is appropriate on cycle.

Outside of this acute use case, letrozole as a routine AI in a normal cycle is almost always unnecessary and frequently causes more problems than it solves.

Using letrozole as a first-line or routine AI on a standard testosterone cycle. This almost universally produces crashed estrogen, joint pain, mood flatness, and degraded training performance, problems that are worse than the estrogen management problem the user was trying to solve.

Continuing letrozole too long after the acute situation resolves. Once active gynecomastia progression has been halted, transitioning to a lower-potency AI (anastrozole or exemestane) is appropriate.

Not measuring estradiol before, during, and after letrozole use. The dose that prevents gynecomastia is different for each user depending on aromatization rate and individual sensitivity. Without labs, there is no way to know whether estrogen is in range or crashed.

Compared with Arimidex, letrozole provides 2–3x more estrogen suppression at comparable doses. For routine estrogen management, anastrozole is almost always the better choice. Letrozole is the emergency option.

Compared with Aromasin, letrozole does not have the steroidal structure or mild androgenic activity. It also does not have exemestane’s irreversibility advantage/disadvantage. All three suppress estrogen, but letrozole does it more aggressively than either of the others.